TC Biopharm Holdings PLC

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDINBURGH, Scotland , Dec. 20, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced 3 patients have now completed the full-dose regimen in the ACHIEVE Phase 2b trial in the UK with no drug-related Adverse Events seen in any of the restart patients. The ACHIEVE UK clinical trial is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease.

TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients

EDINBURGH, Scotland , Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting of shareholders ("GM") at 2:00 p.m.

TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

On Wednesday, TC BioPharm (Holdings) PLC TCBP announced that its Board of Directors approved a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareholder approval.

EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend

CareDx

EDINBURGH, Scotland , Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial. The ACHIEVE clinical trial is an adaptive, open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma delta T cell therapy for patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025 EDINBURGH, Scotland , Dec. 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced an update on the progression of the ACHIEVE UK Trial. As of this week, over half of the Cohort A patients in Stage One of the ACHIEVE study have received TCB008.

TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial

EDINBURGH, Scotland , Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has been awarded non-dilutive funding of $250,000 from the G-Rex® Grant Program.  The G-Rex® Grant Program, launched by ScaleReady alongside Wilson Wolf Manufacturing and the Bio-Techne Corporation, is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing.

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

EDINBURGH, Scotland , Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024. "The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceutical company," said Bryan Kobel, CEO of TC BioPharm.

TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements

TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchange EDINBURGH, Scotland , Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being delisted from the Nasdaq stock exchange.  The since deleted rumor stated that the company had filed an 8-K Notice to "Delist" from the Nasdaq and would transfer trading to a different exchange.

TCBP Responds to False Social Media Claim

EDINBURGH, Scotland , Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox. Dr. Carlos Maluquer de Motes is Reader and Principal Investigator at the University of Surrey, United Kingdom and works closely with The Pirbright Institute, a leading center of excellence in research of viral diseases that spread from animals to humans.

TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic

TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process The software could have additional applications across cell therapy for donor/patient matching EDINBURGH, Scotland , Oct. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the patient screening process. The Company will partner with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the School of Computer Science at the renowned university, and her lab to leverage AI to build a solution that enhances the donor selection process and matching process.

TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening

Additional London-based clinic to increase enrolment velocity Leading hospital with extensive cell therapy and oncology trial experience EDINBURGH, Scotland , Sept. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced new site opening of Guys and St. Thomas Hospital in the ACHIEVE UK Trial.

TCBP Announces Site Opening of Guys and St. Thomas Hospital

EDINBURGH, Scotland , Sept. 24, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer Bryan Kobel has been invited to present at the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York City.

TCBP to Present at the 2024 ThinkEquity Conference in NYC

No TCB008-related Adverse Events seen in any of the re-start patients 6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth dose EDINBURGH, Scotland, Sept. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients.

TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial

EDINBURGH, Scotland , Sept. 9, 2024  /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox.

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox

EDINBURGH, Scotland , Sept. 5, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications today announced it will participate at the H.C.

TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

5 New patients dosed, bringing total to 6 patients dosed in ACHIEVE at higher dose level 5 Patients received second dose 2 Patients received third dose EDINBURGH, Scotland , Sept. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces dosing of 5 new patients in the ACHIEVE Phase 2b trial ongoing in the UK.

TCBP Announces Dosing of 5 New Patients in ACHIEVE

EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering, upsized to 6,000,000 shares of its American Depository Shares ("ADSs")(or pre-funded warrants in lieu thereof), together with Series H warrants ("Series G Warrants") to purchase up to 6,000,000 ADSs at a combined public offering price of $1 per ADS (or pre-funded warrant in lieu thereof) and associated Series H Warrant.  The Series H Warrants have an exercise price of £0.76 per ADS, are exercisable upon issuance and will expire one year from the date of issuance.

TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering

EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has received a patent grant from European Patent Office (EPO) covering the use of modified gamma delta cells for the treatment of cancer and viral indications. The Company intends to proceed with the patent process in specific European countries in line with the commercial strategy of TCBP.

TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications

EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the Company has regained compliance with the Nasdaq Stock Market Listing Rule 5550(b) which will maintain the listing of the Company's American depositary shares on the Nasdaq Global Select Market. On May 24, 2024, the Company received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company was not in compliance with the Minimum Stockholders' Equity Requirement, as of March 31, 2024.

TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)

EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering of 2,000,000 shares of its American Depository Shares ("ADSs")(or pre-funded warrants in lieu thereof), together with Series G warrants ("Series G Warrants") to purchase up to 2,000,000 ADSs at a combined public offering price of $1 per ADS (or pre-funded warrant in lieu thereof) and associated Series G Warrant.  The Series G Warrants have an exercise price of  £0.78 per ADS, are exercisable upon issuance and will expire one year from the date of issuance.

TC BioPharm Announces Closing of $2.0 Million Public Offering

TC BioPharm (NASDAQ: TCBP ) stock is falling on Wednesday after the clinical-stage biopharmaceutical company announced the pricing of a registered direct offering of its shares. TC BioPharm is selling 2 million of its American Depository Shares (ADS) for $1 per share.

Why Is TC BioPharm (TCBP) Stock Down 46% Today?

EDINBURGH, Scotland , Aug. 13, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into definitive agreement for the purchase and sale of 2,000,000 shares of its American Depository Shares and Pre-Funded Warrants at an offering price of $1 per share in a registered direct offering and an additional 2,000,000 cash exercise only Series G warrants with an exercise price of £0.78 with a single investor. The gross proceeds to the Company from the offering are expected to be $2.0 million.

TC BioPharm Announces Pricing of $2.0 Registered Direct Offering

EDINBURGH, Scotland , July 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will change its ratio of its American Depositary Shares ("ADSs") to ordinary shares from one (1) ADS representing twenty (20) ordinary shares to one ADS representing two hundred (200) ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on August 5th, 2024, U.S. Eastern Time.

TCBP Announces Plan to Implement ADS Ratio Change

5 patients treated in "safety cohort" showed no drug related Serious Adverse Events Restart of trial after amendment approved by MHRA to increase dose level EDINBURGH, Scotland , July 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on July 16, the sixth patient in ACHIEVE (UK) was treated.  This is the first patient treated with a higher dose of TCB-008 post the amendment approved by the MHRA on Feb 22, 2024.

TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia

The Company's lead therapeutic will be available through a newly opened compassionate use program EDINBURGH, Scotland , May 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK. Compassionate use refers to the prescription of unlicensed medicinal products to treat a patient in instances where their individual clinical needs cannot be met with the available licensed treatments.

News for TC Biopharm Holdings PLC Stock (TCBP)